



US009284342B2

(12) **United States Patent**
Ross et al.

(10) **Patent No.:** **US 9,284,342 B2**
(45) **Date of Patent:** ***Mar. 15, 2016**

(54) **NUCLEOSIDE PHOSPHORAMIDATES**

(56) **References Cited**

(71) Applicant: **GILEAD PHARMASSET LLC**, Foster City, CA (US)

U.S. PATENT DOCUMENTS

(72) Inventors: **Bruce S. Ross**, El Granada, CA (US); **Michael Joseph Sofia**, Doylestown, PA (US); **Ganapati Reddy Pamulapati**, San Ramon, CA (US); **Suguna Rachakonda**, Twinsburg, OH (US); **Hai-Ren Zhang**, San Jose, CA (US); **Byoung-Kwon Chun**, Robbinsville, NJ (US); **Peiyuan Wang**, Totowa, NJ (US)

3,798,209	A	3/1974	Witkowski et al.
3,852,267	A	12/1974	Meyer, Jr. et al.
RE29,835	E	11/1978	Witkowski et al.
4,814,477	A	3/1989	Wijnberg et al.
4,957,924	A	9/1990	Beauchamp
5,026,687	A	6/1991	Yarchoan et al.
5,118,820	A	6/1992	Hertel
5,149,794	A	9/1992	Yatvin et al.
5,157,027	A	10/1992	Billier et al.
5,192,549	A	3/1993	Barenolz et al.
5,194,654	A	3/1993	Hostetler et al.
5,223,263	A	6/1993	Hostetler et al.
5,256,641	A	10/1993	Yatvin et al.
5,256,798	A	10/1993	Chou et al.
5,372,808	A	12/1994	Blatt et al.
5,376,380	A	12/1994	Kikuchi et al.
5,405,598	A	4/1995	Schinazi et al.
5,411,947	A	5/1995	Hostetler et al.
5,420,266	A	5/1995	Britton et al.
5,426,183	A	6/1995	Kjell
5,453,499	A	9/1995	Chou et al.
5,462,724	A	10/1995	Schinazi et al.
5,463,092	A	10/1995	Hostetler et al.
5,496,546	A	3/1996	Wang et al.
5,538,865	A	7/1996	Reyes et al.
5,543,389	A	8/1996	Yatvin et al.
5,543,390	A	8/1996	Yatvin et al.
5,543,391	A	8/1996	Yatvin et al.
5,554,728	A	9/1996	Basava et al.
5,610,054	A	3/1997	Draper
5,633,358	A	5/1997	Gruetzke et al.
5,633,388	A	5/1997	Diana et al.
5,676,942	A	10/1997	Testa et al.
5,703,058	A	12/1997	Schinazi et al.
5,711,944	A	1/1998	Gilbert et al.

(73) Assignee: **Gilead Pharmasset LLC**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 116 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/925,078**

(22) Filed: **Jun. 24, 2013**

(65) **Prior Publication Data**
US 2013/0288997 A1 Oct. 31, 2013

(Continued)

Related U.S. Application Data

FOREIGN PATENT DOCUMENTS

(63) Continuation of application No. 13/076,552, filed on Mar. 31, 2011, now Pat. No. 8,618,076, which is a continuation-in-part of application No. 12/783,680, filed on May 20, 2010, now Pat. No. 8,642,756.

AU	2010249481	5/2015
CA	2 682 230 A1	10/2008

(Continued)

(60) Provisional application No. 61/319,513, filed on Mar. 31, 2010, provisional application No. 61/319,548, filed on Mar. 31, 2010, provisional application No. 61/179,923, filed on May 20, 2009, provisional application No. 61/319,513, filed on Mar. 31, 2010.

OTHER PUBLICATIONS

Search and Examination Report in African Regional Intellectual Property Organization Application No. APP/2012/006543 dated Jan. 9, 2015.

(Continued)

(51) **Int. Cl.**
C07H 19/10 (2006.01)
A61K 31/7072 (2006.01)
C07H 19/06 (2006.01)
C07H 23/00 (2006.01)
A61K 45/06 (2006.01)
C07F 9/24 (2006.01)

Primary Examiner — Eric Olson
(74) *Attorney, Agent, or Firm* — Sheppard Mullin Richter & Hampton LLP

(52) **U.S. Cl.**
CPC **C07H 19/10** (2013.01); **A61K 31/7072** (2013.01); **A61K 45/06** (2013.01); **C07F 9/2479** (2013.01); **C07H 19/06** (2013.01); **C07H 23/00** (2013.01)

(57) **ABSTRACT**

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

(58) **Field of Classification Search**

(56)

References Cited

U.S. PATENT DOCUMENTS

5,725,859	A	3/1998	Omer	7,148,206	B2	12/2006	Sommadossi et al.
5,738,845	A	4/1998	Imakawa	7,163,929	B2	1/2007	Sommadossi et al.
5,738,846	A	4/1998	Greenwald et al.	7,202,224	B2	4/2007	Eldrup et al.
5,747,646	A	5/1998	Hakimi et al.	7,217,523	B2	5/2007	Wagner
5,767,097	A	6/1998	Tam	7,268,119	B2	9/2007	Cook et al.
5,792,834	A	8/1998	Hakimi et al.	7,307,065	B2	12/2007	Schinazi et al.
5,830,455	A	11/1998	Valtueno et al.	7,323,453	B2	1/2008	Olsen et al.
5,830,905	A	11/1998	Diana et al.	7,365,057	B2	4/2008	LaColla et al.
5,834,594	A	11/1998	Hakimi et al.	7,390,791	B2	6/2008	Becker et al.
5,837,257	A	11/1998	Tsai et al.	7,429,572	B2	9/2008	Clark
5,846,964	A	12/1998	Ozeki	7,601,820	B2	10/2009	Wang et al.
5,849,696	A	12/1998	Chretien et al.	7,608,597	B2	10/2009	Sommadossi et al.
5,869,253	A	2/1999	Draper	7,608,600	B2	10/2009	Storer et al.
5,891,874	A	4/1999	Colacino et al.	7,635,689	B2	12/2009	LaColla et al.
5,905,070	A	5/1999	Schinazi et al.	7,754,699	B2	7/2010	Chun et al.
5,908,621	A	6/1999	Glue et al.	7,879,815	B2	2/2011	MacCoss et al.
5,922,757	A	7/1999	Chojkier	7,964,580	B2	6/2011	Sofia et al.
5,928,636	A	7/1999	Alber et al.	8,148,349	B2	4/2012	Meppen et al.
5,942,223	A	8/1999	Bazer et al.	8,173,621	B2	5/2012	Du et al.
5,980,884	A	11/1999	Blatt et al.	8,334,270	B2	12/2012	Sofia et al.
5,990,276	A	11/1999	Zhang et al.	8,415,322	B2	4/2013	Clark
6,004,933	A	12/1999	Spruce et al.	8,551,973	B2	10/2013	Bao et al.
6,034,134	A	3/2000	Gold et al.	8,563,530	B2	10/2013	Chang et al.
6,043,077	A	3/2000	Barber et al.	8,580,765	B2	11/2013	Sofia et al.
6,056,961	A	5/2000	Lavie et al.	8,618,076	B2*	12/2013	Ross et al. 514/51
6,060,080	A	5/2000	Kikuchi et al.	8,859,756	B2	10/2014	Ross et al.
6,090,932	A	7/2000	McGee et al.	8,916,538	B2*	12/2014	Kuldipkumar C07H 19/06 514/43
6,130,326	A	10/2000	Ramasamy et al.	2001/0034440	A1	10/2001	Shepard et al.
6,132,763	A	10/2000	Fisher	2002/0058635	A1	5/2002	Averett
6,156,501	A	12/2000	McGall et al.	2002/0198173	A1	12/2002	Schinazi et al.
6,180,134	B1	1/2001	Zalipsky et al.	2003/0050229	A1	3/2003	Sommadossi et al.
6,232,300	B1	5/2001	Schinazi et al.	2003/0060400	A1	3/2003	LaColla et al.
6,239,159	B1	5/2001	Brown et al.	2003/0120071	A1	6/2003	McGuigan et al.
6,348,587	B1	2/2002	Schinazi et al.	2003/0144502	A1	7/2003	Pietrzkowski et al.
6,372,883	B1	4/2002	Attwood et al.	2003/0153744	A1	8/2003	Mekouar et al.
6,391,859	B1	5/2002	Schinazi et al.	2003/0187018	A1	10/2003	Llinas-Brunet et al.
6,410,531	B1	6/2002	Llinas-Brunet et al.	2004/0006007	A1	1/2004	Gosselin et al.
6,420,380	B2	7/2002	Llinas-Brunet et al.	2004/0014108	A1	1/2004	Eldrup et al.
6,455,513	B1	9/2002	McGuigan et al.	2004/0023240	A1	2/2004	Marliere et al.
6,455,690	B1	9/2002	Tam et al.	2004/0023901	A1	2/2004	Cook et al.
6,475,985	B1	11/2002	Wagner et al.	2004/0059104	A1	3/2004	Cook et al.
6,479,463	B1	11/2002	Wang et al.	2004/0063622	A1	4/2004	Sommadossi et al.
6,495,677	B1	12/2002	Ramasamy et al.	2004/0067901	A1	4/2004	Bhat et al.
6,509,320	B1	1/2003	Wang et al.	2004/0072788	A1	4/2004	Bhat et al.
6,534,523	B1	3/2003	Llinas-Brunet et al.	2004/0087541	A1	5/2004	Jonaitis et al.
6,552,183	B1	4/2003	Ramasamy et al.	2004/0097461	A1	5/2004	Sommadossi et al.
6,555,677	B2	4/2003	Petrillo et al.	2004/0097462	A1	5/2004	Sommadossi et al.
6,573,248	B2	6/2003	Ramasamy et al.	2004/0101535	A1	5/2004	Sommadossi et al.
6,642,206	B2	11/2003	Ramasamy et al.	2004/0102414	A1	5/2004	Sommadossi et al.
6,660,721	B2	12/2003	Devos et al.	2004/0110717	A1	6/2004	Carroll et al.
6,677,314	B2	1/2004	Klecker et al.	2004/01167140	A1	8/2004	Schinazi et al.
6,677,315	B2	1/2004	Klecker et al.	2004/0191824	A1	9/2004	Dempey et al.
6,680,303	B2	1/2004	Schinazi et al.	2004/0214844	A1	10/2004	Otto et al.
6,682,715	B2	1/2004	Klecker et al.	2004/0229839	A1	11/2004	Babu et al.
6,683,045	B2	1/2004	Klecker et al.	2004/0229840	A1	11/2004	Bhat et al.
6,703,374	B1	3/2004	Klecker et al.	2004/0248892	A1	12/2004	Wang
6,753,309	B2	6/2004	Klecker et al.	2004/0254141	A1	12/2004	Schinazi et al.
6,777,395	B2	8/2004	Bhat et al.	2004/0259934	A1	12/2004	Olsen et al.
6,784,166	B2	8/2004	Devos et al.	2004/0265969	A1	12/2004	Li et al.
6,787,305	B1	9/2004	Li et al.	2004/0266996	A1	12/2004	Rabi
6,787,526	B1	9/2004	Bryant et al.	2005/0009737	A1	1/2005	Clark
6,812,219	B2	11/2004	LaColla et al.	2005/0020825	A1	1/2005	Storer et al.
6,815,542	B2	11/2004	Hong et al.	2005/0026853	A1	2/2005	Mekouar et al.
6,846,810	B2	1/2005	Martin et al.	2005/0031588	A1	2/2005	Sommadossi et al.
6,897,201	B2	5/2005	Boyer et al.	2005/0075309	A1	4/2005	Storer et al.
6,908,924	B2	6/2005	Watanabe et al.	2005/0080034	A1	4/2005	Standring et al.
6,911,424	B2	6/2005	Schinazi et al.	2005/0090660	A1	4/2005	Watanabe et al.
6,914,054	B2	7/2005	Sommadossi et al.	2005/0124532	A1	6/2005	Sommadossi et al.
6,962,991	B2	11/2005	Dempey et al.	2005/0130931	A1	6/2005	Boyer et al.
7,018,985	B1	3/2006	Boyer et al.	2005/0137161	A1	6/2005	Sommadossi et al.
7,018,989	B2	3/2006	McGuigan et al.	2005/0148534	A1	7/2005	Castellino et al.
7,081,449	B2	7/2006	Pietrzkowski et al.	2005/0154056	A1	7/2005	Yang et al.
7,105,493	B2	9/2006	Sommadossi et al.	2005/0164960	A1	7/2005	Olsen et al.
				2005/0215513	A1	9/2005	Boojamra et al.
				2005/0227947	A1	10/2005	Chen et al.
				2005/0261237	A1	11/2005	Boojamra et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2006/0014943 A1 1/2006 Dempcy et al.
 2006/0035866 A1 2/2006 Cannizzaro et al.
 2006/0040890 A1 2/2006 Martin et al.
 2006/0040927 A1 2/2006 Blake et al.
 2006/0040944 A1 2/2006 Gosselin et al.
 2006/0079478 A1 4/2006 Boojamra et al.
 2006/0110727 A9 5/2006 McGall et al.
 2006/0122146 A1 6/2006 Chun et al.
 2006/0122154 A1 6/2006 Olsen et al.
 2006/0142238 A1 6/2006 McGuigan
 2006/0166964 A1 7/2006 Hudyma et al.
 2006/0194749 A1 8/2006 Keicher et al.
 2006/0199783 A1 9/2006 Wang et al.
 2006/0241064 A1 10/2006 Roberts et al.
 2006/0276511 A1 12/2006 Serrano-Wu et al.
 2006/0293306 A1 12/2006 Beaulieu et al.
 2007/0015905 A1 1/2007 LaColla et al.
 2007/0037735 A1 2/2007 Gosselin et al.
 2007/0037773 A1 2/2007 Sommadossi et al.
 2007/0042939 A1 2/2007 LaColla et al.
 2007/0042988 A1 2/2007 Klumpp et al.
 2007/0042990 A1 2/2007 Gosselin et al.
 2007/0049754 A1 3/2007 Boojamra et al.
 2007/0060498 A1 3/2007 Gosselin et al.
 2007/0060541 A1 3/2007 Gosselin et al.
 2007/0087960 A1 4/2007 Storer et al.
 2007/0197463 A1 8/2007 Chun et al.
 2007/0225249 A1 9/2007 Shi
 2007/0265222 A1 11/2007 MacCoss et al.
 2007/0275912 A1 11/2007 Bhat et al.
 2007/0275947 A1 11/2007 Bergstrom
 2008/0070861 A1 3/2008 Clark
 2008/0253995 A1 10/2008 Clark
 2009/0004135 A1 1/2009 Clark
 2009/0036666 A1 2/2009 Clark
 2009/0137521 A1 5/2009 Hamilton et al.
 2009/0176732 A1 7/2009 Beigelman et al.
 2009/0233879 A1 9/2009 Reddy et al.
 2009/0280084 A1 11/2009 Schinazi et al.
 2009/0306007 A1 12/2009 Wagner
 2010/0016251 A1 1/2010 Sofia et al.
 2010/0022468 A1 1/2010 Meppen et al.
 2010/0029008 A1 2/2010 Rojas Stutz et al.
 2010/0035835 A1 2/2010 Narjes et al.
 2010/0048917 A1 2/2010 Wang et al.
 2010/0081628 A1 4/2010 Du et al.
 2010/0137576 A1 6/2010 Stec et al.
 2010/0152128 A1 6/2010 Attenni et al.
 2010/0173863 A1 7/2010 Schinazi et al.
 2010/0227801 A1 9/2010 Hopkins
 2010/0279973 A1 11/2010 Chun et al.
 2010/0286083 A1 11/2010 Bao et al.
 2010/0298257 A1 11/2010 Ross et al.
 2010/0316594 A1 12/2010 Sommadossi et al.
 2011/0015146 A1 1/2011 Sofia et al.
 2011/0124592 A1 5/2011 McGuigan et al.
 2011/0150827 A1 6/2011 Dousson et al.
 2011/0245484 A1 10/2011 Ross et al.
 2011/0251152 A1 10/2011 Ross et al.
 2011/0257122 A1 10/2011 Sofia et al.
 2012/0107278 A1 5/2012 Berrey et al.
 2012/0245335 A1 9/2012 Clark
 2013/0029929 A1 1/2013 Sofia et al.
 2013/0109647 A1 5/2013 Berrey et al.
 2013/0136776 A1 5/2013 Cleary et al.
 2013/0137654 A1 5/2013 Ross et al.
 2013/0165401 A1 6/2013 Ross et al.
 2013/0165644 A1 6/2013 Ross et al.

FOREIGN PATENT DOCUMENTS

CN 101108870 A 1/2008

EP 0 350 287 A2 1/1990
 EP 1 828 217 A2 9/2007
 EP 1 881 001 A1 1/2008
 EP 2 097 430 A1 9/2009
 EP 2 124 555 A2 12/2009
 EP 2 207 786 B1 3/2012
 EP 2552931 7/2014
 JP 5-238939 A 9/1993
 WO 89/02733 A1 4/1989
 WO 90/00555 A1 1/1990
 WO 91/16920 A1 11/1991
 WO 91/18914 A1 12/1991
 WO 91/19721 A1 12/1991
 WO 93/00910 A1 1/1993
 WO 94/26273 A1 11/1994
 WO 95/13090 A1 5/1995
 WO 95/24185 A1 9/1995
 WO 96/15132 A1 5/1996
 WO 96/32403 A2 10/1996
 WO 97/12033 A1 4/1997
 WO 97/36554 A1 10/1997
 WO 98/16184 A2 4/1998
 WO 98/17679 A1 4/1998
 WO 98/22496 A2 5/1998
 WO 99/07734 A2 2/1999
 WO 99/15194 A1 4/1999
 WO 99/32139 A1 7/1999
 WO 99/32140 A1 7/1999
 WO 99/43691 A1 9/1999
 WO 99/59621 A1 11/1999
 WO 99/64016 A1 12/1999
 WO 00/06529 A1 2/2000
 WO 00/09531 A2 2/2000
 WO-00/18775 4/2000
 WO 00/37110 A2 6/2000
 WO 01/09121 A2 2/2001
 WO 01/32153 A2 5/2001
 WO 01/60315 A2 8/2001
 WO 01/79246 A2 10/2001
 WO 01/81359 A1 11/2001
 WO 01/90121 A2 11/2001
 WO 01/91737 A2 12/2001
 WO 01/92282 A2 12/2001
 WO 01/96353 A2 12/2001
 WO 02/08187 A1 1/2002
 WO 02/08198 A2 1/2002
 WO 02/08241 A2 1/2002
 WO 02/08251 A2 1/2002
 WO 02/08256 A2 1/2002
 WO 02/18404 A2 3/2002
 WO 02/32414 A2 4/2002
 WO 02/32920 A2 4/2002
 WO 02/48116 A2 6/2002
 WO 02/48157 A2 6/2002
 WO 02/48165 A2 6/2002
 WO 02/48172 A2 6/2002
 WO 02/057287 A2 7/2002
 WO 02/057425 A2 7/2002
 WO 02/060926 A2 8/2002
 WO 02/100415 A2 12/2002
 WO 03/000713 A1 1/2003
 WO 03/006490 A1 1/2003
 WO 03/010141 A2 2/2003
 WO 03/024461 A1 3/2003
 WO 03/026589 A2 4/2003
 WO 03/037895 A1 5/2003
 WO 03/051899 A1 6/2003
 WO 03/053989 A1 7/2003
 WO 03/061576 A2 7/2003
 WO 03/062256 A1 7/2003
 WO 03/064456 A1 8/2003
 WO 03/068244 A1 8/2003
 WO 03/101993 A1 12/2003
 WO 03/104250 A1 12/2003
 WO 03/105770 A2 12/2003
 WO 03/106477 A1 12/2003
 WO 04/000858 A2 12/2003

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	2004/002944	A1	1/2004	WO	2007/093901	A1	8/2007
WO	2004/002977	A1	1/2004	WO	2007/095269	A2	8/2007
WO	2004/002999	A2	1/2004	WO	2008/010921	A2	1/2008
WO	2004/003000	A2	1/2004	WO	2008/045419	A1	4/2008
WO	2004/003138	A2	1/2004	WO	2008/048128	A1	4/2008
WO	2004/007512	A2	1/2004	WO	2008/062206	A2	5/2008
WO	2004/009020	A2	1/2004	WO	2008/079206	A1	7/2008
WO	2004/009610	A2	1/2004	WO	2008/082601	A2	7/2008
WO	2004/011478	A2	2/2004	WO	2008/085508	A2	7/2008
WO	2004/014313	A2	2/2004	WO	2008121634	A1	9/2008
WO	2004/014852	A2	2/2004	WO	2008121634	A2	10/2008
WO	2004/035571	A1	4/2004	WO	2008/142055	A2	11/2008
WO	2004/041201	A2	5/2004	WO	2009/029844	A1	3/2009
WO	2004/046331	A2	6/2004	WO	2009/052287	A1	4/2009
WO	2004/065367	A1	8/2004	WO	2009/115893	A2	9/2009
WO	2004/080466	A1	9/2004	WO	2009/120878	A2	10/2009
WO	2004/094452	A2	11/2004	WO	2009/129120	A2	10/2009
WO	2004/096210	A1	11/2004	WO	2009/132123	A1	10/2009
WO	2004/096234	A2	11/2004	WO	2009/152095	A2	12/2009
WO	2004/096235	A2	11/2004	WO	WO-2010/004343		1/2010
WO	2004/096286	A2	11/2004	WO	2010/042834	A1	4/2010
WO	2004/106356	A1	12/2004	WO	2010/075517	A2	7/2010
WO	2005/002626	A2	1/2005	WO	2010/075549	A2	7/2010
WO	2005/003147	A2	1/2005	WO	2010/075554	A1	7/2010
WO	2005/007810	A2	1/2005	WO	2010/080878	A1	7/2010
WO	2005/009418	A2	2/2005	WO	2010/081082	A2	7/2010
WO	2005/012327	A2	2/2005	WO	2010135569	A1	11/2010
WO	2005/020884	A2	3/2005	WO	2011/035231	A1	3/2011
WO	2005/021568	A2	3/2005	WO	2011/123672	A1	10/2011
WO	2005/028502	A1	3/2005	WO	WO-2011/123645		10/2011
WO	2005/037214	A2	4/2005	WO	WO-2011/123668		10/2011
WO	2005/067900	A2	7/2005				
WO	2005/072361	A2	8/2005				
WO	2005/082144	A1	9/2005				
WO	2005/087788	A2	9/2005				
WO	2005/095403	A2	10/2005				
WO	2005/103045	A1	11/2005				
WO	2005/123087	A2	12/2005				
WO	2006/000922	A2	1/2006				
WO	2006/012078	A2	2/2006				
WO	2006/012440	A2	2/2006				
WO	2006/020082	A1	2/2006				
WO	2006/029081	A2	3/2006				
WO	2006/031725	A2	3/2006				
WO	2006/035061	A1	4/2006				
WO	2006/037028	A2	4/2006				
WO	2006/050161	A2	5/2006				
WO	2006/063149	A1	6/2006				
WO	2006/063717	A2	6/2006				
WO	2006/065335	A2	6/2006				
WO	2006/065590	A2	6/2006				
WO	2006/067606	A1	6/2006				
WO	2006/093801	A1	9/2006				
WO	2006/100310	A1	9/2006				
WO	2006/116557	A1	11/2006				
WO	2006/120251	A1	11/2006				
WO	2006/120252	A2	11/2006				
WO	2006/121820	A1	11/2006				
WO	2006/121820	A1	11/2006				
WO	2007/002602	A2	1/2007				
WO	2007/014920	A1	2/2007				
WO	2007/014921	A1	2/2007				
WO	2007/014922	A1	2/2007				
WO	2007/014925	A1	2/2007				
WO	2007/014926	A1	2/2007				
WO	2007/015824	A2	2/2007				
WO	2007/020193	A2	2/2007				
WO	2007/027248	A2	3/2007				
WO	2007/039142	A1	4/2007				
WO	2007/039145	A1	4/2007				
WO	2007/065829	A1	6/2007				
WO	2007/070556	A2	6/2007				
WO	2007/076034	A2	7/2007				

OTHER PUBLICATIONS

Communication enclosing Partial European Search Report for European Patent Application No. 13159791.6, dated Feb. 6, 2014 (6 pages).

Office Action in Canadian Application No. 2794669 dated Jan. 15, 2015.

Office Action in Chinese Application No. 201180017181.3 dated Aug. 19, 2014.

Mitchell et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," J. Chem. Soc. Perkin. Trans. 1, pp. 2345-2353 (1992).

Olsen et al., "2'-Modified Nucleoside Analogs as Inhibitors of Hepatitis C RNA Replication," Program and Abstracts, 16th International Conference on Antiviral Research, Abstract No. 121, p. A76 (Apr. 27-May 1, 2003).

Otto, M., "Evaluation of Nucleoside Analogs in the Hepatitis C Virus Replicon System," Framing the Knowledge of Therapeutics for Viral Hepatitis, IHL Press, First Edition, pp. 247-261 (2006).

Piantadosi et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," J. Med. Chem., vol. 34, No. 4, pp. 1408-1414 (1991).

Pierra et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," J. Med. Chem., vol. 49, No. 22, pp. 6614-6620 (2006).

Starrett, Jr. et al., "Synthesis, Oral Bioavailability Determination, and In Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., vol. 37, No. 12, pp. 1857-1864 (1994).

Stuyver et al., "Inhibition of hepatitis C replicon RNA synthesis by B-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication," Antiviral Chemistry & Chemotherapy, vol. 17, No. 2, pp. 79-87 (2006).

Stuyver et al., "Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites," J. Virol., vol. 77, No. 19, pp. 10689-10694 (2003).

Stuyver et al., "Ribonucleoside Analogue that Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture," Antimi-

(56)

References Cited

OTHER PUBLICATIONS

- Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," Fifth Edition, vol. 1, pp. 975-977 (1995).
- Zon, G., "4 Cyclophosphamide Analogues," Progress in Medicinal Chemistry, vol. 19, pp. 205-246 (1982).
- Bhat et al., "Synthesis and Pharmacokinetic Properties of Nucleoside Analogues as Possible Inhibitors of HCV RNA Replication," (Oral Session V: Hepatitis C Virus, Flaviviruses), 16th International Conference on Antiviral Research, Abstract No. 120, p. A75 (Apr. 27-May 1, 2003).
- Chu et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus *Penicillium griseofulvum*," Bioorg. & Med. Chem. Lett., vol. 9, pp. 1949-1952 (1999).
- Chu et al., "Structure of Sch 68631: A New Hepatitis C Virus Protease Inhibitor from *Streptomyces* sp." Tet. Lett., vol. 37, No. 40, pp. 7229-7232 (1996).
- De Lombaert et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors," J. Med. Chem., vol. 37, No. 4, pp. 498-511 (1994).
- Edmundson et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide," J. Chem. Research (S), pp. 122-123 (1989).
- Goekjian et al., "Synthesis of Fluorinated Marcocyclic Bis(indolyl)maleimides as Potential 19F NMR Probes for Protein Kinase C," J. Org. Chem. vol. 64, No. 12, pp. 4238-4246 (1999).
- Hernandez et al., "Synthesis of Highly Functionalized Chiral Nitriles by Radical Fragmentation of beta-Hydroxy Azides. Convenient Transformation of Aldonitriles into 1,4- and 1,5-Iminoalditols," J. Org. Chem., vol. 69, No. 24, pp. 8437-8444 (2004).
- Hostetler et al., "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type 1 Replication in CEM and HT4-6C Cells by 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3'-Deoxythymidine," Antimicrobial Agents and Chemotherapy, vol. 36, No. 9, pp. 2025-2029 (1992).
- Kucera et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," Aids Research and Human Retroviruses, vol. 6, No. 4, pp. 491-501 (1990).
- Meier et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2',3'-dideoxythymidine (d4T)—A New Pro-Nucleotide Approach," Bioorg. & Med. Chem. Lett., vol. 7, No. 2, pp. 99-104, (1997).
- Neidlein et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," Heterocycles, vol. 35, No. 2, pp. 1185-1203 (1993).
- Nifant'ev et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phosphorus, Sulfur, and Silicon, vol. 113, pp. 1-13 (1996).
- Novak, J. J. K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-erythro-D-Pentono-1,4-Lactones," Collection Czechoslov. Chem. Commun., vol. 39, pp. 869-882 (1974).
- Novak, J. J. K., "Nucleic Acid Components and Their Analogues CXLI. Nucleosides Derived from 2-Deoxy-2(R)-C-Methyl-erythro-D-Pentose," Collection Czechoslov. Chem. Commun., vol. 36, pp. 3670-3677 (1971).
- Oishi et al., "Asymmetric Dihydroxylation of Chiral Olefins. High Control of Diastereofacial Selection," Tet. Lett., vol. 34, No. 22, pp. 3573-3576 (1993).
- Shih et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem., Acad. Sin., vol. 41, pp. 9-16, (Mar. 1994).
- Xiao-Ling et al., "Study on the Chirality of Sulfur in Ethyl (2S, 3R,4R)-4,5-O-Isopropylidene-2,3-sulfinyl-1,2,3,4,5-tetrahydroxypentanoate," Acta Chimica Sinica, vol. 55, pp. 600-604 (1997).
- Xiao-Ling et al., "The Synthesis of (2S,3R)-Sphingosine from D-Mannitol," Acta Chimica Sinica, vol. 54, pp. 826-832 (1996).
- International Search Report issued in International Application No. PCT/US2004/012472 mailed Dec. 30, 2004 (4 pages).
- International Search Report issued in International Application No. PCT/US2005/025916 mailed Jun. 15, 2006 (2 pages).
- International Search Report issued in International Application No. PCT/EP2006/069060 mailed Jan. 30, 2007 (4 pages).
- International Search Report issued in International Application No. PCT/US2005/032406 mailed May 8, 2008 (3 pages).
- Bartenschlager et al., "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," J. Virol., vol. 67, No. 7, pp. 3835-3844 (1993).
- Bartenschlager et al., "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing," J. Virol., vol. 68, No. 8, pp. 5045-5055 (1994).
- Bazan et al., "Detection of a Trypsin-like Serine Protease Domain in Flaviviruses and Pestiviruses," Virology, vol. 171, pp. 637-639 (1989).
- Beaulieu et al., "Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections," Current Opinion in Investigational Drugs, vol. 5, No. 8, pp. 838-850 (2004).
- Behrens et al., "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus," The EMBO Journal, vol. 15, No. 1, pp. 12-22 (1996).
- Calisher et al., "Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera," J. Gen. Virol., vol. 70, pp. 37-43 (1989).
- Carroll et al., "Nucleoside Analog Inhibitors of Hepatitis C Virus Replication," Infectious Disorders—Drug Targets, vol. 6, No. 1, pp. 17-29 (2006).
- Eckart et al., "The Hepatitis Polyprotein C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein Precursor," Biochemical and Biophysical Research Communications, vol. 192, No. 2, pp. 399-406 (1993).
- Failla et al., "Both NS3 and NS4A are Required for Proteolytic Processing of Hepatitis C Virus Nonstructural Proteins," J. Virol., vol. 68, No. 6, pp. 3753-3760 (1994).
- Rice, C. M., "Flaviviridae: The Viruses and Their Replication," Fields Virology, 3rd Edition, vol. 1, pp. 931-959 (1996).
- Gorbalenya et al., "A conserved NTP-motif in putative helicases," Nature, vol. 333, p. 22 (1988).
- Gorbalenya et al., "N-terminal domains of putative helicases of flaviviruses and pestiviruses may be serine proteases," Nucleic Acids Research, vol. 17, No. 10, pp. 3889-3897 (1989).
- Grakoui et al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites," J. Virol., vol. 67, No. 5, pp. 2832-2843 (1993).
- Grakoui et al., "A second hepatitis C virus-encoded proteinase," Proc. Natl. Acad. Sci., vol. 90, pp. 10583-10587 (1993).
- Griffith et al., "HCV Anti-viral Agents," Annual Reports in Medicinal Chemistry, vol. 39, pp. 223-237 (2004).
- Halstead, S. B., "Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XI. Dengue," Review of Infectious Diseases, vol. 6, No. 2, pp. 251-263 (1984).
- Furman, Phillip A., et al., "PSI-7851: A Novel Liver-Targeting Nucleotide Prodrug for the Treatment of Hepatitis C," Hepatology (2008) 48(4 Suppl):1161A (Abstract #1901).
- Furman, Phillip A., et al., "PSI-7851: A Novel Liver-Targeting Nucleotide Prodrug for the Treatment of Hepatitis C," Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, Oct. 31-Nov. 4, 2008.
- Furman, P.A., et al., "b-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine Phosphoramidates are Potent and Selective Inhibitors of HCV RNA Replication," Presented at the 15th International Symposium on

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.